报价延迟最少15分钟:2026/04/17 22:50 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.98 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.12/--
|
|
企业价值
79.71M
|
| 资产负债 |
|
每股账面净值
2.99
|
| 现金流量 |
|
现金流量率
0.04
|
| 损益表 |
|
收益
27.64M
|
|
每股收益
1.73
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against theprincipal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line. |
